Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain

Completed

• Conditions: Inflammatory and Oxidative Status in the Spanish Population; Atherosclerosis Risk; Dyslipaemia; Increased hsCRP

• Registration Number: NCT00998062
• Lead Sponsor: AstraZeneca

Brief Summary

The present project is aimed at determining the prevalence of LDL-C \<130 mg/dl with hsCRP ≥2mg/l, and of HDL-C \< 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-10-19
• Study First Submitted QC: 2009-10-19
• Study First Posted: 2009-10-20
• Study Start: 2009-11
• Status Verified: 2011-10
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Last Update Submitted: 2011-10-19
• Last Update Posted: 2011-10-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30181

Inclusion Criteria

• Have an Informed consent form signed when the patient accepted to participate in the study already performed.
• Spanish population between
• Data from Epidemiological studies performed after the year 2000

Exclusion Criteria

• Spanish population outside the age range
• Data from Epidemiological studies performed before the year 2000

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments	retrospectively

Secondary Outcome Measures

Name	Time	Method
High sensitivity C reactive protein & CHR risk by Framingham adapted functions	retrospectively
Lipid profile among the Spanish regions, as in the primary outcome variable	retrospectively
Biomarkers: Interleukines 6 and 10, oxidized LDL, VCAM, ICAM, TNF alpha, neopterin, fibrinogen, lp(a), MMP 9 Apo A, Apo B, adiponectin, leptin, resistin, and yet other	prospectively

Trial Locations

Locations (1)

Research Site; 🇪🇸 Navarra, Spain